HK1081099A1 - Use of myxoma virus for therapeutic treatment of cancer and chronic viral infection - Google Patents

Use of myxoma virus for therapeutic treatment of cancer and chronic viral infection

Info

Publication number
HK1081099A1
HK1081099A1 HK06101073.2A HK06101073A HK1081099A1 HK 1081099 A1 HK1081099 A1 HK 1081099A1 HK 06101073 A HK06101073 A HK 06101073A HK 1081099 A1 HK1081099 A1 HK 1081099A1
Authority
HK
Hong Kong
Prior art keywords
cancer
viral infection
therapeutic treatment
chronic viral
myxoma virus
Prior art date
Application number
HK06101073.2A
Other languages
English (en)
Inventor
Grant Mcfadden
John C Bell
Original Assignee
Robarts Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Robarts Res Inst filed Critical Robarts Res Inst
Publication of HK1081099A1 publication Critical patent/HK1081099A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK06101073.2A 2003-03-07 2006-01-24 Use of myxoma virus for therapeutic treatment of cancer and chronic viral infection HK1081099A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45252103P 2003-03-07 2003-03-07
US45539303P 2003-03-18 2003-03-18
PCT/CA2004/000341 WO2004078206A1 (fr) 2003-03-07 2004-03-08 Utilisation du virus du myxome pour le traitement du cancer et des infections virales chroniques

Publications (1)

Publication Number Publication Date
HK1081099A1 true HK1081099A1 (en) 2006-05-12

Family

ID=32965588

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06101073.2A HK1081099A1 (en) 2003-03-07 2006-01-24 Use of myxoma virus for therapeutic treatment of cancer and chronic viral infection

Country Status (12)

Country Link
US (2) US7582614B2 (fr)
EP (1) EP1601376B1 (fr)
JP (2) JP4800924B2 (fr)
KR (1) KR101116858B1 (fr)
AU (1) AU2004216928C1 (fr)
CA (1) CA2517147C (fr)
HK (1) HK1081099A1 (fr)
IL (1) IL170601A (fr)
MX (1) MXPA05009526A (fr)
NZ (1) NZ541951A (fr)
RU (1) RU2362584C2 (fr)
WO (1) WO2004078206A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05009526A (es) * 2003-03-07 2005-12-15 Robarts Res Inst Uso de virus de mixoma para el tratamiento terapeutico de cancer e infeccion viral cronica.
DE102004003572A1 (de) * 2004-01-23 2005-08-18 Bavarian Nordic A/S Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens
EP1863906A4 (fr) * 2005-03-07 2009-06-03 Robarts Res Inst Combinaison du virus du myxome et de la rapamycine utilisée dans un traitement thérapeutique
WO2007143538A2 (fr) * 2006-06-01 2007-12-13 Robarts Research Institute Pike-a renforçant l'infection par les myxomavirus
NZ572893A (en) 2006-06-01 2011-06-30 Robarts Res Inst Myxoma virus mutants for cancer treatment
DK2717887T3 (en) * 2011-06-09 2018-04-09 Univ Florida Methods for treating or preventing graft-versus-host disease
US20190350992A1 (en) * 2016-11-17 2019-11-21 Vcn Biosciences Sl Use of viral vectors in the treatment of retinoblastoma
CN111065732A (zh) 2017-09-11 2020-04-24 Imba-莫利库尔生物技术研究所 肿瘤类器官模型
KR20190109379A (ko) * 2018-03-16 2019-09-25 바이로큐어 주식회사 암 치료를 위한 레오바이러스 및 믹소마폭스 바이러스의 병용
RU2699754C1 (ru) * 2018-05-08 2019-09-09 Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский национальный исследовательский государственный университет имени Н.Г. Чернышевского" Флуоресцирующая клеточная линия глиомы и способ её получения
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
KR102093623B1 (ko) * 2018-08-17 2020-03-26 바이로큐어 주식회사 암 치료를 위한 다람쥐폭스 바이러스 및 믹소마폭스 바이러스의 병용
SG11202102272UA (en) * 2018-09-05 2021-04-29 Univ Arizona State Oncolytic virus platform to treat hematological cancer
US11591616B1 (en) 2019-04-22 2023-02-28 Colorado State University Research Foundation Apoptotic upregulation by myxoma virus expressing walleye dermal sarcoma virus orfC

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806347A (en) 1985-12-11 1989-02-21 Schering Corporation Interferon combinations
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
EP0895476B1 (fr) 1996-01-25 2003-06-04 The University Court Of The University Of Glasgow Mutant 1716 de hsv destine au traitement des mesotheliomes
CA2296319A1 (fr) 1997-07-18 1999-01-28 Chiron Corporation Vecteurs lentiviraux
ATE371372T1 (de) 1997-10-09 2007-09-15 Wellstat Biologics Corp Behandlung von neoplasmen mit interferon- empfindlichen, klonalen viren
ES2153284B1 (es) 1998-06-10 2001-09-01 Fundacion Para El Estudio Y De Nuevo virus recombinante de mixoma atenuado y su uso en la preparacion de vacunas mixtas contra la mixomatosis y la enfermedad hemorragica de los conejos.
AU4246900A (en) 1999-04-15 2000-11-02 Pro-Virus, Inc. Treatment of neoplasms with viruses
WO2001004318A2 (fr) 1999-07-12 2001-01-18 Viron Therapeutics, Inc. Nouveaux genes de virus de la myxomatose pour immunomodulation
MXPA05009526A (es) * 2003-03-07 2005-12-15 Robarts Res Inst Uso de virus de mixoma para el tratamiento terapeutico de cancer e infeccion viral cronica.
WO2007143545A2 (fr) 2006-06-01 2007-12-13 Robarts Research Institute Signal tnf dans les traitements du virus du myxome

Also Published As

Publication number Publication date
AU2004216928B2 (en) 2007-03-08
US7582614B2 (en) 2009-09-01
RU2005131020A (ru) 2006-03-10
KR101116858B1 (ko) 2012-03-06
KR20050111349A (ko) 2005-11-24
US8227440B2 (en) 2012-07-24
NZ541951A (en) 2008-03-28
CA2517147A1 (fr) 2004-09-16
JP2011157399A (ja) 2011-08-18
AU2004216928C1 (en) 2007-03-08
US20060263333A1 (en) 2006-11-23
EP1601376B1 (fr) 2012-05-30
US20090317362A1 (en) 2009-12-24
JP2006519789A (ja) 2006-08-31
CA2517147C (fr) 2011-06-14
IL170601A (en) 2010-11-30
JP4800924B2 (ja) 2011-10-26
WO2004078206A1 (fr) 2004-09-16
MXPA05009526A (es) 2005-12-15
EP1601376A1 (fr) 2005-12-07
RU2362584C2 (ru) 2009-07-27
AU2004216928A1 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
IL170601A (en) Use of myxoma virus for therapeutic treatment of cancer and chronic viral infection
IL207575A0 (en) Vaccine for prevention and treatment of hiv infection
ZA200410229B (en) Administration of therapeutic viruses
TWI347189B (en) Administration of tlr7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus
EP1594512A4 (fr) Composes destines au traitement d'une infection virale
EP1492563A4 (fr) Compositions et procedes pour le diagnostic et le traitement de l'infection du virus de l'herpes simplex
EP1848418A4 (fr) Utilisation de derives d'acide nordihydroguaiaretique pour traiter des cancers et des infections virales et microbiennes qui resistent aux medicaments
IL185376A0 (en) Use of a combination of myxoma virus and rapamycin for therapeutic treatment
EP1765330A4 (fr) Derives de pyranoindole et utilisation de ceux-ci pour le traitement d'une maladie ou d'une infection provoquee par le virus de l'hepatite c
EP1670507A4 (fr) Vaccin pour le traitement et la prevention de l'infection provoquee par le virus de l'herpes simplex
AU2003225281A8 (en) Materials and methods for prevention and treatment of rna viral diseases
GB0329254D0 (en) Treatment of viral infections
IL178492A0 (en) Cancer treatment using viruses and camptothecins
IL162236A0 (en) Purified hepatitis c virus envelopeproteins for dagnostic and therapeutic use
AU2003225670A1 (en) Interferon drug therapy for the treatment of viral diseases and liver fibrosis
FR12C0058I2 (fr) Medicament pour traiter des maladies de peau virales et des maladies tumorales
EP1525216A4 (fr) Therapie combinee pour le traitement d'infection vih
AU9279601A (en) Compounds and methods for use thereof in the treatment of cancer or viral infections
GB0329958D0 (en) Treatment of viral infections
NO20041855L (no) Fremgangsmate for behandling av hepatitt C-virusinfeksjon ved behandling av feilpasienter
AU2003299962A1 (en) Interferon drug therapy for the treatment of viral diseases and liver fibrosis
AU2003269133A1 (en) Combination treatment of cancer using a cancer vaccine and a chemotherapeutic drug
EP1482955A4 (fr) Traitement prophylactique et therapeutique de maladies infectieuses et autres maladies utilisant des composes immuno-effecteurs
AU2002327531A1 (en) Therapeutic compositions and methods for treating viral infection
AU2003287216A8 (en) Gb virus c and methods of treating viral infections

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210308